Development and preclinical evaluation of an alphavirus replicon vaccine for influenza

Abstract We used a propagation-defective, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the hemagglutinin (HA) and neuraminidase (NA) proteins from influenza A/Wyoming/03/2003 (H3N2). Efficient production methods were scaled to produce pilo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2007-11, Vol.25 (48), p.8180-8189
Hauptverfasser: Hubby, Bolyn, Talarico, Todd, Maughan, Maureen, Reap, Elizabeth A, Berglund, Peter, Kamrud, Kurt I, Copp, Laura, Lewis, Whitney, Cecil, Chad, Norberg, Pamela, Wagner, Jordan, Watson, Aubrey, Negri, Sarah, Burnett, Bruce K, Graham, Andrew, Smith, Jonathan F, Chulay, Jeffrey D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract We used a propagation-defective, single-cycle, alphavirus replicon vector system to produce virus-like replicon particles (VRP) expressing the hemagglutinin (HA) and neuraminidase (NA) proteins from influenza A/Wyoming/03/2003 (H3N2). Efficient production methods were scaled to produce pilot lots of HA VRP and NA VRP and clinical lots of HA VRP. HA VRP-induced high-titered antibody responses in mice, rabbits and rhesus macaques, as measured by ELISA or hemagglutination inhibition (HI) assays, and robust cellular immune responses in mice and rhesus macaques, as measured by IFN-γ ELISPOT. NA VRP also induced cellular immune responses in mice. A toxicology study with HA VRP and NA VRP in rabbits showed no adverse effects in any parameter. These studies support clinical testing of alphavirus replicon vaccines for influenza.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2007.09.038